FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $225 | +341.2% | 21,352 | +97.5% | 0.00% | – |
| Q2 2023 | $51 | -17.7% | 10,811 | 0.0% | 0.00% | – |
| Q1 2023 | $62 | -43.1% | 10,811 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $109 | -100.0% | 10,811 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $242,000 | -9.7% | 10,811 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $268,000 | -36.0% | 10,811 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $419,000 | -33.8% | 10,811 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $633,000 | -1.2% | 10,811 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $641,000 | -31.7% | 10,811 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $938,000 | +5.3% | 10,811 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $891,000 | -9.4% | 10,811 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $983,000 | +127.5% | 10,811 | 0.0% | 0.01% | +150.0% |
| Q3 2020 | $432,000 | +16.4% | 10,811 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $371,000 | +54.6% | 10,811 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $240,000 | – | 10,811 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 716,392 | $11,126,000 | 12.18% |
| Polaris Venture Management Co. V, L.L.C. | 1,139,783 | $17,701,000 | 10.06% |
| Grosvenor Holdings, L.L.C. | 2,285,714 | $35,497,000 | 6.41% |
| Redmile Group, LLC | 11,216,809 | $174,197,000 | 5.83% |
| Casdin Capital, LLC | 2,550,000 | $39,601,500,000 | 4.10% |
| DAFNA Capital Management LLC | 470,000 | $7,299,000 | 2.74% |
| Ghost Tree Capital, LLC | 350,000 | $5,436,000 | 1.38% |
| Artal Group S.A. | 2,000,000 | $31,060,000 | 1.24% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,952,897 | $30,328,000 | 1.24% |
| Copernicus Capital Management, LLC | 75,000 | $1,165,000 | 1.08% |